Use of carboxypeptidase e/neurotrophic factor-alpha1 to treat neurodegenerative disease
AssigneeThe U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorYoke Peng LOH
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to use of Carboxypeptidase E (CPE) for treating or preventing onset or progression of a neurodegenerative disease.
Claims23
A method of treating a neurodegenerative disease or preventing onset or progression of a neurodegenerative disease in a subject in need thereof, comprising administering a mouse or human Carboxypeptidase E (CPE) protein to the subject, wherein the CPE protein comprises the amino acid sequence set forth in SEQ ID NO:
- 2, 4, 6, 8, 11, or 14;
- and wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease (AD), Parkinson's disease (PD), dementia, frontotemporal dementia (FTD), depression, bipolar disorder, amyotrophic lateral sclerosis (ALS), spinal cord injury, traumatic brain injury (TBI), stroke, ischemia, and Down's syndrome.
(canceled)
(canceled)
The method of claim 21, wherein the CPE protein is CPE-E342Q comprising the amino acid sequence set forth in SEQ ID NO:6 or SEQ ID NO:8.
The method of claim 21, wherein the CPE protein is a N-terminal-truncated variant (CPE-ΔN), wherein the amino acid sequence of the CPE protein consists of the sequence set forth in SEQ ID NO:11 or SEQ ID NO:14.
(canceled)
-44. (canceled)
Dependencies are inferred from the claim text.